{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:57:13Z","timestamp":1770080233490,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clinthera.2023.09.015","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T08:33:18Z","timestamp":1697099598000},"page":"1289-1292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized Minimal Effective Concentration Therapy"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-8024","authenticated-orcid":false,"given":"Philip D.","family":"Walson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.09.015_bib0001","first-page":"458","article-title":"Individualization of drug therapy: history, present state, and opportunities for the future","volume":"92","author":"Lesko","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0002","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/jamaoncol.2022.4452","article-title":"All optimal dosing roads lead to therapeutic drug monitoring-why take the slow lane","volume":"8","author":"Beumer","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0003","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/0024-3205(67)90218-4","article-title":"Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds","volume":"6","author":"Hammer","year":"1967","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0004","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/ajt.16002","article-title":"A comprehensive review of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation","volume":"20","author":"Gonzales","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0005","unstructured":"Perucca E, Piani F. Dose-response relationship and therapeutic drug monitoring. pg. 201-214, in Dose response relationships in clinical pharmacology: proceedings of the Esteve Foundation Symposium III. Published in 1989, ICS808, Editors: L. Lasagna, S. Erill, C.A. Naranjo, L. Lasagna, S. Erill, C.A. Naranjo."},{"key":"10.1016\/j.clinthera.2023.09.015_bib0006","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.3.5770.331","article-title":"Relationship between plasma level and therapeutic effect of nortriptyline","volume":"3","author":"\u00c0sberg","year":"1971","journal-title":"Brit Med J"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1176\/ajp.142.2.155","article-title":"Tricyclic antidepressants-blood level measurements and clinical outcome","volume":"142","year":"1985","journal-title":"Am J Psych"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0008","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00007691-198103000-00014","article-title":"The ultrafree drug filters: need for closer evaluation","volume":"3","author":"Perucca","year":"1981","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0009","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2203\/dose-response.09-049.Reynolds","article-title":"Potential relevance of bell-shaped and U-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer","volume":"8","author":"Reynolds","year":"2010","journal-title":"Dose Response"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/20014091111785","article-title":"Estrogen and related compounds: biphasic dose responses","volume":"31","author":"Calabrese","year":"2001","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/20014091111848","article-title":"Opiates: biphasic dose responses","volume":"31","author":"Calabrese","year":"2001","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0012","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/bcp.14434","article-title":"TDM is dead. Long live TCI","volume":"88","author":"Holford","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0013","series-title":"Essential Pharmacokinetics: A Primer for Pharmaceutical Scientists","first-page":"1","article-title":"A primer for pharmaceutical scientists","year":"2015"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0014","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/TP.0000000000003651","article-title":"Donor-derived cell-free DNA in solid-organ transplant diagnostics: indications, limitations, and future directions","volume":"105","author":"Kataria","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10408363.2017.1299683","article-title":"Using circulating cell-free DNA to monitor personalized cancer therapy","volume":"54","author":"Oellerich","year":"2017","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0016","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/B978-1-4557-0268-8.00097-X","article-title":"Long-term toxicity of immunosuppressive therapy","author":"Ruiz","year":"2015","journal-title":"Transplant Liver"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0017","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cei.12988","article-title":"Immune monitoring as prerequisite for transplantation tolerance trials","volume":"189","author":"Sani","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0018","series-title":"Personalized Immunosuppression in Transplantation","article-title":"Graft-derived cell-free DNA as a marker of graft integrity after transplantation","author":"Oellerich","year":"2016"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0019","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.kint.2021.11.034","article-title":"Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study","volume":"101","author":"Bu","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/TP.0000000000003725","article-title":"Graft-derived cell-free DNA as a noninvasive biomarker of cardiac allograft rejection: a cohort study on clinical validity and confounding factors","volume":"106","author":"Kn\u00fcttgen","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002286","article-title":"Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study","volume":"14","author":"Sch\u00fctz","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1031894","article-title":"Donor-derived cell-free DNA as a diagnostic tool in transplantation","volume":"13","author":"Oellerich","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0023","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0024","unstructured":"UD Food and Drug Administration. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases; Draft Guidance for Industry; Availability [Fed Reg online]. 2023. Available at: https:\/\/www.federalregister.gov\/documents\/2023\/01\/18\/2023-00837."},{"key":"10.1016\/j.clinthera.2023.09.015_bib0025","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","article-title":"Review of therapeutic drug monitoring of anticancer drugs part 1\u2014cytotoxics","volume":"50","author":"Paci","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0026","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-020-03067-9","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0027","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","article-title":"Signatures of copy number alterations in human cancer","volume":"606","author":"Steele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2023.09.015_bib32","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-17-0231","article-title":"Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy","volume":"23","author":"Weiss","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0028","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1634\/theoncologist.2019-0054","article-title":"Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy","volume":"24","author":"J\u00f8rgensen","year":"2019","journal-title":"Oncologist;"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0029","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cpt.1808","article-title":"Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology","volume":"108","author":"Janssen","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Dutch Pharmacology Oncology Group (DPOG). Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2023.09.015_bib0031","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182300379X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182300379X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:59:36Z","timestamp":1758963576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182300379X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S014929182300379X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Minimal Effective Concentration Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}